Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists spy on lung bugs to unlock COPD secrets

NCT ID NCT04849104

Knowledge-focused Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 210 people with COPD over 4 years to see how bacteria and other microbes in the airways relate to lung function decline. Researchers collect fluid from the lungs during a bronchoscopy and analyze the microbial DNA. The goal is to understand why COPD gets worse in some people, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify which airway bacteria or fungi are linked to COPD worsening, pointing toward future diagnostic or treatment targets.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve patient health, and results may not lead to new therapies for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

outpatient or hospitalized patient

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have the ability to communicate orally or in writing and sign an informed consent form; 2. Age from 18 to 70 years (the age of patients with mild to moderate COPD \<75 years), regardless of gender; 3. Meet the above-mentioned early diagnosis criteria for high-risk patients with COPD/early-stage COPD/mild to moderate COPD. Exclusion Criteria: 1. Patients suffering from any of the following diseases: active tuberculosis, severe bronchiectasis, lung abscess, aspiration pneumonia, lung tumor, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pneumothorax, pleural effusion , Pulmonary embolism, pulmonary eosinophilic infiltration, and pulmonary vasculitis; 2. Patients with a history of tumors or patients with current tumors; 3. The patient has severe renal impairment: creatinine clearance rate \<30ml/min/1.73m2 or serum creatinine\>265μmol/L (\>3mg/dL); 4. Patients suffering from liver disease or severe liver damage: ALT, AST\> 2 times the upper limit of normal; 5. pregnancy; 6. Severe COPD, FEV1 predicted value ≤50%; 7. Severe heart disease, such as coronary heart disease, heart failure, etc.; 8. Severe coagulopathy: INR\>1.4, PTT\>40s, PLT\<150x103 cells 9. Bronchial Asthma; 10. Severe alcoholism; 11. diabetes; 12. Have used antibiotics within two months, 13. Used systemic and local hormones; 14. Cannot sign the informed consent form;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, 200011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.